These results prompted us to hypothesize that angiotensin II acts as an angiogenic and tumour-progressive factor for ovarian cancer, and that AT1R may have clinical potential as a novel molecular target or as a prognostic indicator in the treatment of ovarian cancer, as well as in other gynaecological malignancies. The gene discussed is AGT; the disease is ovarian carcinoma.